Welcome to our dedicated page for Iradimed news (Ticker: IRMD), a resource for investors and traders seeking the latest updates and insights on Iradimed stock.
iRadimed Corporation (NASDAQ: IRMD) is focused on MRI-compatible medical devices, and its news flow reflects that specialization. The company regularly issues press releases describing its financial results, product clearances, board changes, and capital allocation decisions. Investors and observers following IRMD news can see how its non-magnetic IV infusion pump systems and MRI-compatible patient vital signs monitoring systems perform in the marketplace and how management communicates about growth and operations.
Recent news has highlighted record quarterly revenue over multiple consecutive quarters, along with updates on gross margins, domestic and international sales mix, and cash flow from operations. The company also reports on its use of non-GAAP financial measures such as non-GAAP net income, non-GAAP diluted earnings per share, and free cash flow, explaining how these metrics relate to its GAAP results. Dividend announcements, including regular quarterly cash dividends and a special cash dividend, are another recurring theme in iRadimed’s news releases.
Product and regulatory developments are also covered in detail. For example, iRadimed announced FDA 510(k) clearance for its MRidium 3870 IV Infusion Pump System, described as a next-generation MRI-compatible infusion pump with a non-magnetic ultrasonic motor, non-interfering RF emissions, and advanced safety and user interface features. News items also describe the capabilities of the 3880 MRI-compatible patient vital signs monitoring system, which operates in magnetic fields up to 30,000 gauss and is designed to travel with patients between critical care units and MRI suites.
Governance and recognition-related news includes disclosures about changes in the Board of Directors and iRadimed’s inclusion in TIME’s list of America’s Growth Leaders for 2026. Conference participation announcements and earnings call schedules provide additional context for those who want to follow company presentations and management commentary. For anyone tracking IRMD, this news feed offers a consolidated view of its financial performance, product milestones, governance updates, and other corporate developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
IRADIMED CORPORATION (NASDAQ: IRMD) will announce its 2023 first quarter financial results before markets open on May 4th, followed by a conference call at 11:00 a.m. ET. Interested participants can register online to join the call, which will also be streamed live on their website. The company is known for its innovative MRI-compatible medical devices, including the MRidium® IV infusion pump and the iRadimed 3880 vital signs monitoring system, designed for safety and efficiency during MRI procedures. These products utilize non-magnetic components to eliminate risks associated with traditional devices in high-field MRI environments, enhancing patient care.
IRADIMED CORPORATION (NASDAQ: IRMD) announced that CEO Roger Susi will present at the 35th Annual Roth Conference on March 13, 2023, at 11:30 am PT in Laguna Niguel, CA. The event will feature 1-on-1 meetings, thematic panels, and presentations from around 400 companies. A live webcast and replay of the fireside chat will be available on Iradimed’s investor page. Iradimed is known for its innovative MRI-compatible medical devices, including its patented MRidium® IV infusion pump system, designed to ensure safety during MRI procedures. The company also manufactures the 3880 MRI-compatible patient vital signs monitoring system, enhancing patient care during MRI scans.
IRADIMED CORPORATION (NASDAQ: IRMD) issued an Urgent Medical Device Correction Letter regarding potential issues with the 1057 Syringe Adapter Set. This device may experience reduced flow and inlet occlusion during use with the MRidium infusion pump, impacting an estimated 0.4% of recently manufactured sets. The company received five customer complaints, none resulting in injury or death. This proactive measure is taken with FDA knowledge and does not affect other products. Importantly, IRADIMED does not anticipate any material financial impact from this corrective action.
IRADIMED CORPORATION (NASDAQ: IRMD) reported strong financial results for Q4 and full-year 2022. Revenue for Q4 reached $14.9 million, up from $11.9 million in Q4 2021, while full-year revenue was $53.3 million, compared to $41.8 million in 2021. GAAP diluted EPS for Q4 was $0.29, and $1.02 for the year. The company announced a special cash dividend of $1.05 per share, payable on February 21, 2023. For 2023, IRADIMED expects revenue between $61 million and $63 million with diluted EPS guidance of $1.10 to $1.20.
IRADIMED CORPORATION (NASDAQ: IRMD) will announce its 2022 Q4 financial results on February 2, 2023, before market opening. Following the release, management will host a conference call at 11:00 a.m. ET to discuss the results and engage with investors. Participants can register for the call and access it via a unique dial-in number provided post-registration. IRADIMED specializes in MRI-compatible medical devices, notably their MRidium® intravenous infusion pump system and the 3880 patient vital signs monitoring system, both of which enhance patient safety during MRI procedures.